RITHCLAR™ 250

Clarithromycin is a second-generation semi-synthetic macrolide antibiotic derived from erythromycin. It inhibits bacterial protein synthesis by binding reversibly to the 50S ribosomal subunit — specifically to the 23S ribosomal RNA — blocking the translocation step of the elongation cycle. This prevents the ribosome from moving along the mRNA, halting polypeptide chain elongation and stopping bacterial protein production.

Compared to first-generation macrolides (erythromycin), clarithromycin offers three significant pharmacokinetic advantages: superior acid stability (does not degrade in gastric acid, unlike erythromycin), higher oral bioavailability (~55% versus ~25% for erythromycin), and a longer elimination half-life (3–7 hours versus 1.5 hours) enabling twice-daily dosing versus erythromycin's four-times-daily regimen. This translates directly into better compliance and treatment completion rates.

Clarithromycin's spectrum is notable for two extensions beyond standard macrolides: it covers Mycobacterium avium complex (MAC) — making it the cornerstone of MAC prophylaxis and treatment in HIV patients — and it is the most pharmacologically active macrolide for H. pylori eradication when combined with amoxycillin and a proton pump inhibitor (standard triple therapy). Its tissue concentrations are 10–20 times higher than plasma levels, with particularly high penetration into lung tissue, bronchial secretions, and skin — explaining its effectiveness in respiratory and dermatological infections.

RITHCLAR™ 250 is indicated for mild to moderate bacterial infections in adults and adolescents above 12 years where macrolide therapy is clinically appropriate, particularly for respiratory infections with atypical pathogen involvement, H. pylori eradication, and skin infections.

Community-Acquired Pneumonia: First-line or combination therapy for mild CAP, particularly in patients at risk for atypical organism involvement (Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella pneumophila). Clarithromycin is recommended in combination with a beta-lactam for hospitalised CAP patients by IDSA/ATS guidelines.

Acute Exacerbations of Chronic Bronchitis: H. influenzae, M. catarrhalis, and S. pneumoniae coverage for COPD exacerbations — the twice-daily regimen improves compliance versus erythromycin.

Acute Bacterial Sinusitis and Otitis Media: ENT infections where standard penicillins have failed or are contraindicated.

H. pylori Eradication: The essential macrolide component of triple therapy (clarithromycin 500mg + amoxycillin 1g + PPI, twice daily for 14 days). For mild infections where 250mg formulations are used, note that H. pylori eradication typically requires 500mg — use RITHCLAR™ 500 for this indication.

Skin and Soft Tissue Infections: Erysipelas, impetigo, and cellulitis caused by streptococci and staphylococci, particularly in penicillin-allergic patients.

MAC Prophylaxis: Prevention of Mycobacterium avium complex in HIV-positive patients with CD4 counts below 50 cells/μL.

Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.